News Some good news for BMS with Opdivo + natural killer cell com... But BMS dumps combination with Yervoy.
Views & Analysis Immuno-oncology: how to keep ahead in a fast-moving field In the last two years, the first PD-1 checkpoint inhibitor drugs to reach patients have launched a revolution in cancer care.
Partner Content Partner Content Ensuring a more informed and effective oncology drug develop... The rush to discover the next big frontier in cancer medicine is more evident than it ever has been since the introduction of targeted therapies.
Partner Content Partner Content VIDEO: Streamlining the process of patient enrollment Ever more-specific cancer medicines carry the advantage of more personalised treatments for those with the disease.
Partner Content Partner Content VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution? The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking to monitor and measure efficacy in patients.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
